AGING IS THE NEXT FRONTIER OF INNOVATION Not because it’s a poetic idea, but because aging is biology, and biology is technology. We’ve spent decades reinventing the digital world while accepting the human body as something fixed and unchangeable. That assumption is about to collapse. I’ve spent years testing treatments most people won’t hear about […]
MATHIAS LOBENDAHL – FOUNDER, LIFESEEDS Read More »
In Estonia, where wood has shaped livelihoods for centuries, one company is reimagining its potential for the next industrial era. Fibenol is transforming undervalued hardwood and plywood industry residues into high-purity biomaterials that offer sustainable alternatives to fossil-based inputs. Its mission is both simple and bold: To help industries defossilize their value chains and accelerate
FIBENOL – DEFOSSILIZING THE FUTURE OF MATERIALS AND CHEMICALS Read More »
Some of the most meaningful innovations don’t begin with a grand plan. They begin when you hit a wall. A few years ago, we were developing a new therapeutic antibody. To really understand it, we had to figure out where it grabbed onto its target molecule—and what happened to that target once the antibody latched
DANIEL X JOHANSSON – CSO & CO-FOUNDER, AAX BIOTECH Read More »
In the heart of Sweden’s thriving life sciences ecosystem, a young biotechnology company is redefining how the world understands and engineers therapeutic antibodies. Founded by researchers from the prestigious Karolinska Institutet, AAX Biotech is on a mission to transform antibody-based medicine—turning scientific breakthroughs into next-generation therapies for some of the world’s most challenging diseases. Science-driven,
AAX BIOTECH – PIONEERING THE NEXT WAVE OF PRECISION ANTIBODY THERAPEUTICS Read More »
I studied molecular science because I wanted to understand how things work. I built a strong knowledge of molecular processes, but the turning point came when my mother was diagnosed with melanoma. I could explain the disease in detail, but I couldn’t change its course. That loss shifted my focus from curiosity alone to curiosity
PROF. MART USTAV – CHIEF EXECUTIVE OFFICER, ICOSAGEN GROUP Read More »
On Northern Europe’s digital frontier, Icosagen stands out in the biotechnology landscape. Based in Tartu, Estonia’s second‑largest city, it is not only the country’s largest biotech company but also one of the most agile Contract Research, Development and Manufacturing Organizations (CRDMOs) operating globally. What truly sets Icosagen apart is its identity — privately held, family‑led,
ICOSAGEN – ESTONIA’S INDEPENDENT BIOTECH PIONEER WITH GLOBAL REACH Read More »
When I was a young researcher, I believed invention was the pinnacle of achievement. To discover something new and build something no one had built before – that felt like enough. But after launching several deep tech startups, I’ve learned a powerful lesson. Invention is just the beginning. Innovation is what changes the world. The
MOHAMAD TAKWA – CEO & CO-FOUNDER, EPIGENICA Read More »
There must be more MDs and PhDs per capita in a 10-mile radius of Rockville, Maryland, than anywhere else in the country. Montgomery County is the foundation of the Biotech Corridor, a dynamic hub for life science research, innovation, and commercialization, with 13,000 private sector employees and 400 life sciences companies. Rockville is undoubtedly the
THE BIOTECH CORRIDOR – WHERE INNOVATION LEADS Read More »
Not long ago, decoding DNA was the holy grail of biology. Today, a growing number of scientists and clinicians believe that the key to the next generation of healthcare lies in understanding how our genes are controlled – epigenetics. Epigenica, a Swedish biotech company founded by Dr. Mohamad Takwa and Prof. Simon Elsässer, is turning
EPIGENICA – DEMOCRATIZING LARGE-SCALE EPIGENOMICS FOR THE AGE OF PERSONALIZED HEALTHCARE Read More »
Life Sciences Nova Scotia (LSNS) is more than just an organization; it is the cornerstone of Nova Scotia’s life sciences community, fostering growth, innovation, and collaboration across the province and Atlantic Canada. At its core, LSNS is driven by the belief that transformative ideas in biotechnology, healthcare, and pharmaceuticals can improve lives and generate lasting
LIFE SCIENCES NOVA SCOTIA – BUILDING A THRIVING COMMUNITY Read More »
As the CEO of Life Sciences Nova Scotia, I have the privilege of witnessing firsthand the creativity, resilience, and vision of the people and companies driving change in the life sciences sector. From pioneering healthcare solutions to cutting-edge biotechnology developments, the Atlantic region is making a profound impact both locally and globally. This book is
DORIS GRANT – CEO, LIFE SCIENCES NOVA SCOTIA Read More »
In a world of rapidly rising temperatures and unstable growing conditions, Potato Improver is reshaping the future of agriculture by empowering one of the world’s most essential food crops—potatoes—to thrive in heat-stressed environments. Founded with a singular mission to safeguard global food security, this Swedish biotech startup has developed a breakthrough CRISPR/Cas-based technology that enables
POTATO IMPROVER – ENGINEERING RESILIENCE IN THE AGE OF CLIMATE CHANGE Read More »
Sightera Biosciences accelerates drug discovery with an innovative approach that combines chemical structure analysis with complex patient-relevant preclinical models to design novel therapies. Due to the organization’s exclusive research collaboration with the DrugVision.AI screening platform of the University of Antwerp/UZA, it can produce exclusive datasets from patient-derived models to train its AI-driven engine, focusing on
Sightera – Complex Patient-Derived Biology Meets AI-Drug Design Read More »
TACKLING THE CHALLENGES OF WATER QUALITY MANAGEMENT: XELEMENT TECHNOLOGY LEADS THE WAY As climate change accelerates, the effects on our environment become more pronounced. Rising temperatures, erratic weather patterns, and dwindling resources create a host of problems, with water quality being acritical concern. Warmer temperatures and oxygen depletion disrupt the delicate balance of aquatic ecosystems,
XElement Technology Read More »
NovelYeast is an R&D company with world-leading expertise in the design and development of superior industrial yeast strains. Our superior yeast strains for bioethanol and isobutanol production support the transition to a more sustainable bio-based economy in the sectors of automobile and aviation transport. Superior yeast strains for production of bio-based chemicals support reduction of
NOVELYEAST-SUPERIOR YEAST AS A TARGET AND A TOOL Read More »
Geno.Me is a biotechnology company that was born from the idea of empowering people to take greater ownership of their health data, because it is a valuable and necessary asset to advance medical research. With a focus on creating better ways to treat populations that have diseases with a genetic predisposition, the organization allows people
GENO.ME, A REAL-WORLD APPROACH TO BETTER CLINICAL RESEARCH OUTCOMES Read More »
IMUNOVA-EXPLORE THE MOST ADVANCED TECHNIQUES IN ANIMAL RESEARCH, ALONG WITH BIOTECHNOLOGICAL SOLUTIONS FOR PRODUCT DEVELOPMENT AND DIAGNOSTICS. Imunova: Pioneering Breakthroughs in Biotechnology for Animal Health Curitiba (Brazil)-based biotechnology firm, Imunova, is at the forefront of innovation in animal health, dedicated to testing and developing cutting edge products for the veterinary industry. Established in 2011 as
BIOPHARMA INVESTMENT FIRM SYRIDEX BIO ADDRESSES HEALTH EQUITY BY FUNDING R&D OF THERAPIES DISPROPORTIONATELY AFFECTING UNDERSERVED POPULATIONS. Princeton-based Syridex Bio is a biopharma investment firm that makes early-stage, venture creation investments in innovative treatments that can bring transformative changes to diseases disproportionately affecting underserved communities. It is uniquely focused on double bottom-line returns, delivering compelling
TransBIOTech, centre collégial de transfert en Biotechnologie, a été fondé en 1999 à la demande du Cégep de Lévis et s’appuie sur ses programmes techniques en biotechnologies et chimie analytique. Organisme à but non lucratif, TransBIOTech se spécialise en démonstrations d’efficacité et d’innocuité sur des composés actifs naturels destinés aux produits du mieuxêtre ou encore
TransBIOTech-CCTT EN BIOTECHNOLOGIES Read More »
Founded in 1999 at the request of the Cégep de Lévis, TransBIOTech is a college centre for biotech transfer that draws on the Cégep’s biotechnolog y and analytical chemistry technical programs. As a non-profit organization, we focus on demonstrating the efficacy and safety of natural active compounds for use in wellness products and of compounds
TransBIOTech-CCTT IN BIOTECHNOLOGY Read More »
Readers of this publication know that Quebec is an incredibly fertile breeding ground for innovation. One of the reasons we generate so much innovation in Quebec is that we have mobilizing organizations in place that catalyze our expertise and knowledge. Among these organizations, the Québec Biotechnology Innovation Centre (QBIC) stands out. Created in 1996, QBIC
Les lecteurs de cette publication sont bien placés pour le savoir : le Québec est un terreau incroyablement fertile pour l’innovation. Si on génère autant d’innovations en sol québécois, c’est notamment parce que nous avons en place des organisations mobilisatrice qui catalyse notre expertise et notre savoir. Parmi ces organisations, le Centre québécois d’innovation en
A LEADER IN BIOFABRICATIONModern Meadow, headquartered in Nutley, NJ, is a sustainable bio-design technology company that uses nature-inspired proteins to develop solutions that reduce our reliance on petrochemical and animal-derived inputs. The company creates solutions that make sustainable high-performance materials possible. Modern Meadow is a protein design and application powerhouse, creating next-generation materials using synthetic
Thus, the CÉPROCQ, early on, based its strategic priorities on green chemistry and sustainable development, which have now become essential to the growth of the industry. The CÉPROCQ is one of the few centers in Quebec, or even in Canada, to offer a research infrastructure on a pilot scale, thereby filling a gap in the